Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of 6MW3211 alone or with azacitidine with or without venetoclax in AML or MDS
CTR20230174Phase 2Terminated
- Sponsor
- Maiwei Biotech
- Start
- Jul 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of 6MW3211 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Maiwei Biotech. Started Jul 2022; status: terminated.
02
Drugs
6MW3211
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20230174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230174.